Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in type 2 diabetes mellitus

Diabetic Medicine

Volumn 17, Issue 3, 2000, Pages 225-229

  Whitelaw, Donald C ^a,b   Clark, P M ^a   Smith, J M ^a   Nattrass, M ^a  

^a Selly Oak Hospitals   (United Kingdom)

^b BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

Insulin secretion; Nateglinide; Type 2 diabetes mellitus

Indexed keywords

INSULIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; MALE; MIDDLE AGED; PHENYLALANINE; PLACEBOS; PROINSULIN;

EID: 0011091161     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00256.x     Document Type: Article

References (18)

1. 1 Malaisse WJ. Stimulation of insulin release by non-sulphonylurea hypoglycaemic agents: the meglitinide family. Horm Metab Res 1995; 27: 263-266.
2. + concentrations. Pharmacol Res 1995; 32: 111-114.
3. 3 Sato Y, Nishikawa M, Shinkai H, Sukegawa E. Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animals. Diab Res Clin Pract 1991; 12: 53-59.
4. 4 Viñambres C, García-Martínez JA, Villanueva-Peñacarrillo ML, Valverde I, Malaisse WJ. Preservation of nutrient-stimulated biosymhetic activity in pancreatic islets exposed to a meglitinide analogue. Med Sci Res 1995; 23: 779-780.
5. 5 Stappenbeck R, Hodson AW, Skillen AW, Agius L, Alberti KGMM. Optimized methods to measure acetoacetate, 3-hydroxybutyrate, glycerol, alanine, pyruvate, lactate and glucose in human blood using a centrifugal analyser with a fluorimetric attachment. J Automatic Chemistry 1990; 12: 213-220.
6. 6 Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray IP et al. Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin. 65-66 split and 32-33 split proinsulins. Biochem J 1989; 260: 535-541.
7. 7 Armitage P, Berry G. Statistical Methods in Medical Research. 3rd Edn. Oxford: Blackwell, 1994.
8. 8 Koschmann M, Alford FP, Ward GM, Walters J, Colman PG, Harrison LC. Reproducibility of estimating first phase insulin responses to intravenous glucose. Diab Nutr Metab 1992; 5: 73-79.
9. 9 Porte D Jr, Pupo AA. Insulin responses to glucose: evidence for a two pool system in man. J Clin Invest 1969; 48: 2309-2319.
10. 10 Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am J Med 1981; 70: 579-588.
11. 11 Metz SA, Halter JB, Robertson RP. Paradoxical inhibition of insulin secretion by glucose in human diabetes mellitus. J Clin Endocrinol Metab 1979; 48: 827-835.
12. 12 Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976; 42: 222-229.
13. 13 Pfeifer MA, Halter JB, Graf R, Porte D Jr. Potentiation of insulin secretion to nonglucose stimuli in normal man by tolbutamide. Diabetes 1980; 29: 335-340.
14. 14 Siegal AM, Kreisberg RA, Owen WC, Fox OJ. Some aspects of 'acute phase' insulin release in healthy subjects. Diabetes 1972; 21: 157-162.
15. 15 Turtle JR. Glucose and insulin secretory response pattern following diet and tolazamide therapy in diabetes. Br Med J 1970; 3: 606-610.
16. 16 Chiasson J-L, Hamet P, Verdy M. The effect of Diamicron on the secretion and action of insulin. Diab Res Clin Pract 1991; 14: S47-S52.
17. 17 Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ. Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency. Diabetes Res 1994; 27: 81-87.
18. 18 DeFronzo RA, Bonnadonna RC, Ferrannini E. Pathogenesis of NIDDM. a balanced overview. Diabetes Care 1992; 15: 318-368.